Fresenius SE & Co. KGaA (LON:0OO9)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 22.68B +6.2% |
| Revenue (ttm) | 20.05B +3.4% |
| Net Income | 1.31B +35.3% |
| EPS | 2.33 +35.3% |
| Shares Out | n/a |
| PE Ratio | 17.31 |
| Forward PE | 12.32 |
| Dividend | 0.92 (2.28%) |
| Ex-Dividend Date | May 25, 2026 |
| Volume | 3,906 |
| Open | 47.12 |
| Previous Close | 47.08 |
| Day's Range | 46.91 - 47.57 |
| 52-Week Range | 35.13 - 52.82 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]
Financial Performance
In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.
Financial numbers in EUR Financial StatementsNews
Fresenius SE price target raised to EUR 52 from EUR 49 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Fresenius SE (FSNUY) to EUR 52 from EUR 49 and keeps an Overweight rating on the shares. Published first…
Fresenius SE price target lowered to EUR 55.20 from EUR 56.60 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 55.20 from EUR 56.60 and keeps an Overweight rating on the shares. Published first on…
Fresenius SE price target raised to EUR 56 from EUR 55 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs raised the firm’s price target on Fresenius SE (FSNUY) to EUR 56 from EUR 55 and keeps a Buy rating on the shares. Published first…
Fresenius Announces Climb In Q2 Bottom Line
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius (FSNPF.PK) reported a profit for its second quarter that Increases, from the same period last yearThe company's earnings totaled EUR382 million, or ...
Fresenius SE & Co. KGaA Earnings Call Transcript: Q2 2026
Strong Q2 results featured double-digit EPS and EBIT growth, margin expansion, and robust cash flow, prompting an upgrade in full-year EPS guidance to 10%-15%. Growth was broad-based across Biopharma, MedTech, and Helios, with continued operational momentum and strategic flexibility.
Fresenius SE & Co. KGaA Slides: Q2 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Fresenius SE & Co. KGaA Earnings release: Q2 2026
Fresenius SE & Co. KGaA released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q2 2026
Fresenius SE & Co. KGaA has published its Q2 2026 quarterly earnings report on August 5, 2026.
Fresenius Raises 2026 Earnings Guidance on Strong Performance
Fresenius accelerates its growth trajectory, lifting 2026 earnings guidance as robust Q2 results, rising margins and solid segment performance underscore its strategic momentum.
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast / Full year Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performa...
Fresenius announces FDA approval of rituximab biosimilar
Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed by Dr. Reddy’s Laboratories, a biosimilar ...
Fresenius Kabi: Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan (rituximab) Rituximab is a CD20-directed cytolytic antibody used across multip...
Fresenius Kabi: Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
U.S. FDA and EMA acceptance for review of Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, of intravenous vedolizumab biosimilar candidate, an integ...
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
BAD HOMBURG, Germany, July 23, 2026 /PRNewswire/ -- The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its ...
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Shares in several European and Asian makers of generic medicines fell after President Trump said the U.S. would place tariffs on such drugs starting in August 2028.
Fresenius SE price target raised to EUR 49 from EUR 48 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Fresenius SE (FSNUY) to EUR 49 from EUR 48 and keeps an Overweight rating on the shares. Published first…
Fresenius Backs Annual Adj. Earnings Growth Outlook
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius (FSNPF.PK, FSNUF.PK, FRE.DE), a German healthcare company, on Monday reaffirmed its annual adjusted earnings growth guidance.For fiscal 2026, exclud...
Fresenius SE price target lowered to EUR 48 from EUR 56 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 48 from EUR 56 and keeps an Overweight rating on the shares. Published first…
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% organic revenue and 13% core EPS growth, with strong contributions from Kabi and Helios. Balance sheet strength improved, S&P upgraded the credit outlook, and full-year guidance was reconfirmed amid ongoing geopolitical and regulatory uncertainty.
Fresenius SE & Co. KGaA Slides: Q1 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Fresenius SE & Co. KGaA Earnings release: Q1 2026
Fresenius SE & Co. KGaA released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q1 2026
Fresenius SE & Co. KGaA has published its Q1 2026 quarterly earnings report on May 6, 2026.
Fresenius SE price target lowered to EUR 53 from EUR 57 at Citi
Citi lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 53 from EUR 57 and keeps a Buy rating on the shares.
Fresenius SE price target lowered to EUR 56 from EUR 58 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 56 from EUR 58 and keeps an Overweight rating on the shares. Published first…